New FDA-Approved UTI Treatment

The FDA has approved Orlynvah, a new oral antibiotic that may offer hope for male patients with urinary incontinence who experience recurrent urinary tract infections (UTIs). Managing UTIs in men can be challenging, especially when standard antibiotics fail due to resistance or underlying conditions.

Orlynvah combines sulopenem etzadroxil and probenecid, a formulation that enhances antibiotic retention in the body, improving its effectiveness against resistant bacteria such as E. coli, Klebsiella pneumoniae, and Proteus mirabilis. This targeted approach could be particularly beneficial for men prone to complicated UTIs due to bladder dysfunction or catheter use.

FDA approval was based on two large clinical trials, demonstrating Orlynvah’s comparable or superior efficacy to common antibiotics like ciprofloxacin and amoxicillin. Side effects were generally mild, including diarrhea, nausea, yeast infections, and headaches.

Men with conditions such as kidney stones, gout, or antibiotic allergies should consult their healthcare provider before using Orlynvah. While initially approved for uncomplicated infections, its effectiveness against resistant bacteria suggests potential benefits for male patients with chronic UTIs linked to urinary incontinence.

Das, J. (2024, October 29). FDA OKs new drug for urinary tract infections. Medscape. https://www.medscape.com/s/viewarticle/fda-oks-new-drug-urinary-tract-infections-2024a1000jqq